Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T16:52:41.322Z.
Calculation as of: 2026-10-06T16:52:41.322Z.
Quote observation: 2026-10-06T16:41:12.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: c2871aed35905ca893ff96a4b2ab646902ae69530b401aedab5470ff00d0a486
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Optimi Health Corp.
Market Cap
$13.33M
EV/EBIT Ratio
N/A
| NAME | MARKET CAP | EV/EBIT RATIO |
|---|---|---|
| Optimi Health Corp. (OPTH) | $13.33M | N/A |
| IN8bio, Inc. (INAB)vs › | $13.71M | N/A |
| Vyome Holdings, Inc. (HIND)vs › | $13.66M | N/A |
| Cellectar Biosciences, Inc. (CLRB)vs › | $12.78M | N/A |
| Passage Bio, Inc. (PASG)vs › | $12.88M | N/A |
| Citius Pharmaceuticals, Inc. (CTXR)vs › | $13.78M | N/A |
| Cytosorbents Corporation (CTSO)vs › | $12.77M | N/A |
| Sintx Technologies, Inc. (SINT)vs › | $13.92M | N/A |
| Dare Bioscience, Inc. (DARE)vs › | $12.57M | N/A |
| Obsidian Therapeutics Inc. (OBX)vs › | $14.10M | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
